MedTrace Logo

Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis

NCT04308616 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2022-06-01

No results posted yet for this study

Summary

Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis.

Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time.

A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.

Conditions

Interventions

OTHER

Blood samples

Blood samples

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Laurent MACHET, MD-PhD · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2022-04-27
Completion
2022-04-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04308616 on ClinicalTrials.gov